肝移植治疗肝门部胆管癌的研究进展

温培豪; 郭文治

doi:10.12449/JCH251204

肝移植治疗肝门部胆管癌的研究进展

DOI: 10.12449/JCH251204

温培豪,
郭文治^, ,

郑州大学第一附属医院肝胆胰外科，河南省肝移植中心，郑州 450052

基金项目:

国家重点研发计划 (2022YFC2304701);

河南省慈善总会肝胆相照基金 (GDXZ2019003)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：温培豪负责文献检索与稿件撰写；郭文治负责研究构思、文稿修改与定稿；温培豪、郭文治负责审阅并批准终稿。

详细信息

通信作者:
郭文治， fccguowz@zzu.edu.cn（ORCID： 0000-0002-0821-1318）

计量
- 文章访问数: 33
- HTML全文浏览量: 16
- PDF下载量: 11
- 被引次数: 0
出版历程
- 收稿日期: 2025-10-23
- 录用日期: 2025-12-01
- 出版日期: 2025-12-25

Research advances in liver transplantation in treatment of perihilar cholangiocarcinoma

Peihao WEN,
Wenzhi GUO^{,
,}

Department of Hepatopancreatobiliary Surgery，The First Affiliated Hospital of Zhengzhou University，Henan Liver Transplantation Center，Zhengzhou 450052，China

Research funding:

National Key Research and Development Program of China (2022YFC2304701);

Liver Health Foundation of Henan Charity Federation (GDXZ2019003)

More Information

Corresponding author: GUO Wenzhi， fccguowz@zzu.edu.cn（ORCID： 0000-0002-0821-1318）

摘要

摘要: 肝门部胆管癌（pCCA）起源于肝左右肝管汇合处的胆管上皮，因其解剖位置复杂、早期症状隐匿、肿瘤生物学行为侵袭性强，导致患者多在晚期确诊。尽管根治性切除仍是首选治疗手段，但术后5年生存率不高。自Mayo Clinic提出术前新辅助放化疗结合严格筛选标准以来，肝移植治疗pCCA的远期生存显著改善。随着供肝来源拓展、活体肝移植技术成熟及免疫抑制策略优化，肝移植已逐步成为特定人群中pCCA的标准化治疗方案之一。本文系统论述肝移植治疗pCCA的临床现状、适应证标准、术前新辅助放化疗策略、术后管理及复发防控进展，并探讨未来发展方向，包括精准分子分型、免疫治疗联合方案以及供肝资源优化等。
- 胆管肿瘤 /
- 肝移植 /
- 肿瘤辅助疗法 /
- 免疫疗法
Abstract: Perihilar cholangiocarcinoma （pCCA） originates from the biliary epithelium at the confluence of the left and right hepatic ducts， and most patients are in the advanced stage at the time of confirmed diagnosis due to complex anatomy， insidious early symptoms， and highly aggressive tumor biology. Although radical resection remains the preferred treatment method， there is still a low 5-year survival rate after surgery. Since Mayo Clinic proposed a protocol combining neoadjuvant chemoradiotherapy with strict screening criteria， long-term outcomes of pCCA have been significantly improved after liver transplantation. With the expansion of donor liver sources， the maturation of living-donor liver transplantation techniques， and the optimization of immunosuppression strategies， liver transplantation has gradually become a standardized treatment regimen for specific patients with pCCA. This article systematically reviews the current status of liver transplantation for the treatment of pCCA， the criteria for indications， the strategies for neoadjuvant therapy before surgery， postoperative management， and recurrence prevention and control， as well as the directions for future development such as precise molecular subtyping， combined immunotherapy， and the optimization of donor organ resources.
- Bile Duct Neoplasms /
- Liver Transplantation /
- Neoadjuvant Therapy /
- Immunotherapy

HTML全文

参考文献(48)

[1]	HAN ZL, PENG JF, NIU T, et al. Progress in surgical treatment of anal cholangiocarcinoma[J]. Chin J Hepatobiliary Surg, 2023, 29( 1): 71- 75. DOI: 10.3760/cma.j.cn113884-20220802-00312. 韩昭龙, 彭俊峰, 牛婷, 等. 肝门部胆管癌的外科治疗进展[J]. 中华肝胆外科杂志, 2023, 29( 1): 71- 75. DOI: 10.3760/cma.j.cn113884-20220802-00312.
[2]	BRINDLEY PJ, BACHINI M, ILYAS SI, et al. Cholangiocarcinoma[J]. Nat Rev Dis Primers, 2021, 7( 1): 65. DOI: 10.1038/s41572-021-00300-2.
[3]	PASCALE A, ROSMORDUC O, DUCLOS-VALLÉE JC. New epidemiologic trends in cholangiocarcinoma[J]. Clin Res Hepatol Gastroenterol, 2023, 47( 9): 102223. DOI: 10.1016/j.clinre.2023.102223.
[4]	BANALES JM, MARIN JJG, LAMARCA A, et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17( 9): 557- 588. DOI: 10.1038/s41575-020-0310-z.
[5]	RASSAM F, ROOS E, van LIENDEN KP, et al. Modern work-up and extended resection in perihilar cholangiocarcinoma: The AMC experience[J]. Langenbecks Arch Surg, 2018, 403( 3): 289- 307. DOI: 10.1007/s00423-018-1649-2.
[6]	GROOT KOERKAMP B, WIGGERS JK, ALLEN PJ, et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection[J]. J Am Coll Surg, 2015, 221( 6): 1041- 1049. DOI: 10.1016/j.jamcollsurg.2015.09.005.
[7]	van KEULEN AM, BUETTNER S, OLTHOF PB, et al. Comparing survival of perihilar cholangiocarcinoma after R1 resection versus palliative chemotherapy for unresected localized disease[J]. Ann Surg Oncol, 2024, 31( 10): 6495- 6503. DOI: 10.1245/s10434-024-15582-5.
[8]	FRANKEN LC, SCHREUDER AM, ROOS E, et al. Morbidity and mortality after major liver resection in patients with perihilar cholangiocarcinoma: A systematic review and meta-analysis[J]. Surgery, 2019, 165( 5): 918- 928. DOI: 10.1016/j.surg.2019.01.010.
[9]	WIGGERS JK, GROOT KOERKAMP B, CIESLAK KP, et al. Postoperative mortality after liver resection for perihilar cholangiocarcinoma: Development of a risk score and importance of biliary drainage of the future liver remnant[J]. J Am Coll Surg, 2016, 223( 2): 321- 331. e 1. DOI: 10.1016/j.jamcollsurg.2016.03.035.
[10]	MEYER CG, PENN I, JAMES L. Liver transplantation for cholangiocarcinoma: Results in 207 patients[J]. Transplantation, 2000, 69( 8): 1633- 1637. DOI: 10.1097/00007890-200004270-00019.
[11]	MORIS D, KOSTAKIS ID, MACHAIRAS N, et al. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis[J]. PLoS One, 2019, 14( 7): e0220527. DOI: 10.1371/journal.pone.0220527.
[12]	HEIMBACH JK, GORES GJ, HADDOCK MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma[J]. Semin Liver Dis, 2004, 24( 2): 201- 207. DOI: 10.1055/s-2004-828896.
[13]	GULAMHUSEIN AF, SANCHEZ W. Liver transplantation in the management of perihilar cholangiocarcinoma[J]. Hepat Oncol, 2015, 2( 4): 409- 421. DOI: 10.2217/hep.15.30.
[14]	GEISSLER EK, SCHNITZBAUER AA, ZÜLKE C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100( 1): 116- 125. DOI: 10.1097/TP.0000000000000965.
[15]	DARWISH MURAD S, KIM WR, HARNOIS DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers[J]. Gastroenterology, 2012, 143( 1): 88- 98. e3; quize 14. DOI: 10.1053/j.gastro.2012.04.008.
[16]	TAN EK, TANER T, HEIMBACH JK, et al. Liver transplantation for peri-hilar cholangiocarcinoma[J]. J Gastrointest Surg, 2020, 24( 11): 2679- 2685. DOI: 10.1007/s11605-020-04721-4.
[17]	BOWLUS CL, ARRIVÉ L, BERGQUIST A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma[J]. Hepatology, 2023, 77( 2): 659- 702. DOI: 10.1002/hep.32771.
[18]	BREUER E, MUELLER M, DOYLE MB, et al. Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? results from an international benchmark study[J]. Ann Surg, 2022, 276( 5): 846- 853. DOI: 10.1097/SLA.0000000000005641.
[19]	CAMBRIDGE WA, FAIRFIELD C, POWELL JJ, et al. Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma[J]. Ann Surg, 2021, 273( 2): 240- 250. DOI: 10.1097/SLA.0000000000003801.
[20]	HOOGWATER FJH, KUIPERS H, de MEIJER VE, et al. Role of neoadjuvant chemoradiotherapy in liver transplantation for unresectable perihilar cholangiocarcinoma: Multicentre, retrospective cohort study[J]. BJS Open, 2023, 7( 2): zrad025. DOI: 10.1093/bjsopen/zrad025.
[21]	YANG J, XIE Y, TIAN DZ, et al. Comparison of survival benefits between liver transplantation combined with neoadjuvant therapy and radical hepatectomy for resectable hilar cholangiocarcinoma[J]. Chin J Hepatobiliary Surg, 2021, 27( 4): 270- 273. DOI: 10.3760/cma.j.cn113884-20200612-00315. 杨健, 谢炎, 田大治, 等. 可切除肝门部胆管癌肝移植联合新辅助治疗与根治性肝切除的生存获益对比[J]. 中华肝胆外科杂志, 2021, 27( 4): 270- 273. DOI: 10.3760/cma.j.cn113884-20200612-00315.
[22]	YIN DL, LIU LX. Application value of neoadjuvant therapy in preoperative descending treatment of locally advanced hilar cholangiocarcinoma[J]. Chin J Dig Surg, 2020, 19( 12): 1253- 1256. DOI: 10.3760/cma.j.cn115610-20201208-00771. 尹大龙, 刘连新. 新辅助治疗在局部晚期肝门部胆管癌术前降期治疗中的应用价值[J]. 中华消化外科杂志, 2020, 19( 12): 1253- 1256. DOI: 10.3760/cma.j.cn115610-20201208-00771.
[23]	Society for Hepato-pancreato-biliary Surgery of Chinese Research Hospital Association, Editorial Board of Chinese Journal of Digestive Surgery. Guideline for diagnosis and treatment of perihilar cholangiocarcinoma(2025 edition)[J]. Chin J Dig Surg, 2025, 24( 1): 1- 20. DOI: 10.3760/cma.j.cn115610-20250106-00010. 中国研究型医院学会肝胆胰外科专业委员会,《中华消化外科杂志》编辑委员会. 肝门部胆管癌诊断和治疗指南(2025版)[J]. 中华消化外科杂志, 2025, 24( 1): 1- 20. DOI: 10.3760/cma.j.cn115610-20250106-00010.
[24]	HEIMBACH JK, GORES GJ, HADDOCK MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma[J]. Transplantation, 2006, 82( 12): 1703- 1707. DOI: 10.1097/01.tp.0000253551.43583.d1.
[25]	DARWISH MURAD S, KIM WR, THERNEAU T, et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma[J]. Hepatology, 2012, 56( 3): 972- 981. DOI: 10.1002/hep.25629.
[26]	WELLING TH, FENG M, WAN SS, et al. Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma[J]. Liver Transpl, 2014, 20( 1): 81- 88. DOI: 10.1002/lt.23757.
[27]	LOVEDAY BPT, KNOX JJ, DAWSON LA, et al. Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada[J]. J Surg Oncol, 2018, 117( 2): 213- 219. DOI: 10.1002/jso.24833.
[28]	ABDELRAHIM M, AL-RAWI H, ESMAIL A, et al. Gemcitabine and cisplatin as neo-adjuvant for cholangiocarcinoma patients prior to liver transplantation: Case-series[J]. Curr Oncol, 2022, 29( 5): 3585- 3594. DOI: 10.3390/curroncol29050290.
[29]	FU XB, QI H, QIU ZK, et al. Outcomes of two types of iodine-125 seed delivery with metal stents in treating malignant biliary obstruction: A systematic review and meta-analysis[J]. Diagn Interv Radiol, 2023, 29( 3): 509- 519. DOI: 10.5152/dir.2022.211277.
[30]	NASSER-GHODSI N, EATON JE, SMITH BH, et al. Transplantation within 6 months of registration does not enhance survival for patients with perihilar cholangiocarcinoma[J]. Ann Surg, 2024. DOI: 10.1097/SLA.0000000000006433.
[31]	VUGTS JJA, GASPERSZ MP, ROOS E, et al. Eligibility for liver transplantation in patients with perihilar cholangiocarcinoma[J]. Ann Surg Oncol, 2021, 28( 3): 1483- 1492. DOI: 10.1245/s10434-020-09001-8.
[32]	LINE PD, YAQUB S, LASSEN K, et al. A novel transplant approach for locally advanced unresectable perihilar cholangiocarcinoma: The SURE-LT concept[J]. Ann Surg, 2025. DOI: 10.1097/SLA.0000000000006892.
[33]	MANSOOR J, HEATON N, JUNAID Z. Current state of liver transplantation for cholangiocarcinoma: A comprehensive literature review[J]. Exp Clin Transplant, 2024, 22( 3): 167- 179. DOI: 10.6002/ect.2023.0343.
[34]	TAN EK, ROSEN CB, HEIMBACH JK, et al. Living donor liver transplantation for perihilar cholangiocarcinoma: Outcomes and complications[J]. J Am Coll Surg, 2020, 231( 1): 98- 110. DOI: 10.1016/j.jamcollsurg.2019.12.037.
[35]	ITO T, TAURA K, FUKUMITSU K, et al. Safety and efficacy of living donor liver transplantation for unresectable perihilar cholangiocarcinoma: A single center prospective study[J]. J Hepatobiliary Pancreat Sci, 2025, 32( 4): 276- 286. DOI: 10.1002/jhbp.12121.
[36]	GIOVINAZZO F, PASCALE MM, CARDELLA F, et al. Current perspectives in liver transplantation for perihilar cholangiocarcinoma[J]. Curr Oncol, 2023, 30( 3): 2942- 2953. DOI: 10.3390/curroncol30030225.
[37]	AHMED O, VACHHARAJANI N, CHANG SH, et al. Single-center experience of liver transplantation for perihilar cholangiocarcinoma[J]. HPB, 2022, 24( 4): 461- 469. DOI: 10.1016/j.hpb.2021.08.940.
[38]	NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47( 9): 1003- 1010. DOI: 10.1038/ng.3375.
[39]	GUO CG, LIU ZQ, YU Y, et al. TP53/KRAS co-mutations create divergent prognosis signatures in intrahepatic cholangiocarcinoma[J]. Front Genet, 2022, 13: 844800. DOI: 10.3389/fgene.2022.844800.
[40]	XIAN F, REN DC, BIE J, et al. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: A meta-analysis[J]. Front Immunol, 2023, 14: 1119168. DOI: 10.3389/fimmu.2023.1119168.
[41]	LIU D, HEIJ LR, CZIGANY Z, et al. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma[J]. J Exp Clin Cancer Res, 2022, 41( 1): 127. DOI: 10.1186/s13046-022-02340-2.
[42]	ORTIZ V, LOEUILLARD E. Rethinking immune check point inhibitors use in liver transplantation: Implications and resistance[J]. Cell Mol Gastroenterol Hepatol, 2025, 19( 1): 101407. DOI: 10.1016/j.jcmgh.2024.101407.
[43]	GOYAL L, MERIC-BERNSTAM F, HOLLEBECQUE A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma[J]. N Engl J Med, 2023, 388( 3): 228- 239. DOI: 10.1056/NEJMoa2206834.
[44]	VOGEL A, SAHAI V, HOLLEBECQUE A, et al. An open-label study of pemigatinib in cholangiocarcinoma: Final results from FIGHT-202[J]. ESMO Open, 2024, 9( 6): 103488. DOI: 10.1016/j.esmoop.2024.103488.
[45]	ZHU AX, MACARULLA T, JAVLE MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial[J]. JAMA Oncol, 2021, 7( 11): 1669- 1677. DOI: 10.1001/jamaoncol.2021.3836.
[46]	LI ZH, TANER T, EATON JE, et al. Development of the perihilar cholangiocarcinoma risk estimation of tumor recurrence after transplant(PRETREAT) score[J]. Ann Surg, 2025, 282( 3): 503- 514. DOI: 10.1097/SLA.0000000000006815.
[47]	YU J, HE AR, OUF M, et al. Detecting early recurrence with circulating tumor DNA in stage I-III biliary tract cancer after curative resection[J]. JCO Precis Oncol, 2025, 9: e2400443. DOI: 10.1200/PO-24-00443.
[48]	YOO C, JEONG H, JEONG JH, et al. Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma[J]. J Hepatol, 2025, 82( 5): 861- 870. DOI: 10.1016/j.jhep.2024.10.043.